The patient was treated as part of the mimics 3d usa post-market observational study.On the (b)(6) 2021, the patient was implanted with one biomimics 3d (bm3d) stent, a 6.0 x 60mm stent which was used to treat a denovo lesion of the superficial femoral artery (sfa) proximal third in the left leg.A contralateral approach was used and the lesion was prepared using pre-dilation with percutaneous transluminal angioplasty (pta) balloon and atherectomy.The treated segment was also post-dilated with pta.The site reported that on (b)(6) 2022, an event of limb ischemia was identified.It was reported as not related to the device and not related to the procedure but due to a worsening pre-existing condition.A severe in-stent stenosis was also identified.It was reviewed by veryan's chief medical officer on (b)(6) 2023, this was considered to be possibly related to the device.The limb ischemia was treated with a surgical graft bypass and endarterectomy of the sfa proximal third and distal popliteal artery on 06-oct-22.It was reported as a target vessel revascularisation (tvr).The patient outcome was reported as resolved with sequelae and the device remains implanted.
|
There was no reported device malfunction and the device was not returned for analysis.A review has been performed of the manufacturing certificate of conformance associated with this lot.There were no non-conformances or deviations which could be associated with this event.Based on the case information and related record review, a conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.The reported patient effect of restenosis leading to intervention and limb ischemia are listed in the biomimics 3d instructions for use and are known patient effect of peripheral stenting procedures.There is no indication of a product quality issue with respect to the design, manufacture or labelling of the device.If further information regarding this event becomes available, a follow-up report will be submitted.
|